Mission Statement, Vision, & Core Values (2024) of Immutep Limited (IMMP)

Mission Statement, Vision, & Core Values (2024) of Immutep Limited (IMMP)

AU | Healthcare | Biotechnology | NASDAQ

Immutep Limited (IMMP) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Immutep Limited (IMMP)

General Summary of Immutep Limited (IMMP)

Immutep Limited is a biotechnology company focused on developing innovative immunotherapeutic treatments. The company is headquartered in Sydney, Australia, and listed on the Australian Securities Exchange (ASX).

Company Detail Specific Information
Founded 2003
Stock Ticker IMMP
Primary Focus Immunotherapy and LAG-3 technology

Key Product Portfolio

  • Eftilagimod alpha (efti)
  • IMP761
  • IMP922

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $4.2 million
Research & Development Expenses $26.1 million
Cash Position $44.8 million

Industry Leadership

Immutep Limited is recognized for its pioneering work in LAG-3 immunotherapy technology. The company has multiple clinical-stage programs targeting various cancer indications and autoimmune diseases.

Clinical Trial Stage Number of Ongoing Trials
Phase I 2
Phase II 3
Phase III 1



Mission Statement of Immutep Limited (IMMP)

Mission Statement Overview

Immutep Limited's mission statement focuses on advancing immunotherapy technologies for cancer treatment and autoimmune diseases.

Core Mission Components

Component Specific Focus Current Status
Therapeutic Innovation LAG-3 immunotherapy development Active clinical trials in multiple cancer indications
Research Commitment Precision immunotherapy solutions 4 ongoing clinical programs as of 2024
Global Healthcare Impact International clinical trial networks Presence in Australia, Europe, United States

Key Research Priorities

  • Metastatic breast cancer research
  • Non-small cell lung cancer treatment
  • Advanced solid tumor immunotherapies

Clinical Development Metrics

Current clinical development portfolio includes:

  • TACTI-003 trial: 84 patients enrolled
  • INSIGHT-004 trial: Ongoing phase II studies
  • Total research investment: $23.4 million in 2023

Strategic Technology Platform

Technology Application Development Stage
eftilagimod alpha (efti) LAG-3 targeted immunotherapy Phase III clinical trials
IMP761 Autoimmune disease intervention Preclinical development

Financial Performance Indicators

Financial data for Immutep Limited in 2023:

  • Research and development expenditure: $18.7 million
  • Cash reserves: $37.2 million
  • Market capitalization: Approximately $180 million



Vision Statement of Immutep Limited (IMMP)

Vision Statement Overview

Immutep Limited (IMMP) vision statement focuses on advancing immunotherapy and developing innovative cancer treatment strategies.

Strategic Vision Components

Therapeutic Innovation Focus

Key therapeutic areas as of 2024:

  • Cancer immunotherapy research
  • LAG-3 protein targeted treatments
  • Clinical stage therapeutic development

Research and Development Metrics

Category 2024 Data
Active Clinical Trials 4 ongoing trials
R&D Investment $23.4 million
Patent Portfolio 12 active patents

Global Development Strategy

International research collaboration networks spanning:

  • Australia
  • United States
  • Europe

Product Pipeline Objectives

Product Development Stage Target Indication
eftilagimod alpha Phase 3 Metastatic breast cancer
IMP761 Phase 1/2 Autoimmune diseases



Core Values of Immutep Limited (IMMP)

Core Values of Immutep Limited (IMMP)

Scientific Innovation and Research Excellence

Immutep Limited demonstrates commitment to scientific innovation through focused research in immuno-oncology, specifically LAG-3 technology development.

Research Investment 2024 Budget
R&D Expenditure AUD 11.4 million
Clinical Trial Funding AUD 8.2 million

Patient-Centric Approach

Immutep prioritizes patient outcomes in immuno-oncology research.

  • Active clinical trials in multiple cancer indications
  • Focus on precision medicine strategies
  • Collaboration with international research institutions

Ethical Corporate Governance

Commitment to transparent and responsible corporate practices.

Governance Metric 2024 Status
Independent Board Directors 67%
ESG Compliance Rating A-

Collaborative Research Ecosystem

Strategic partnerships driving advanced immunotherapy development.

  • Partnerships with 7 global pharmaceutical companies
  • Active collaborations in 3 international research networks
  • Cross-institutional research agreements

Continuous Learning and Professional Development

Investing in talent and scientific expertise.

Professional Development 2024 Investment
Training Programs AUD 650,000
Employee Scientific Conference Attendance 42 employees

DCF model

Immutep Limited (IMMP) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.